KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBIT: 2011-2025

Historic EBIT for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $24.9 million.

  • Travere Therapeutics' EBIT rose 144.40% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.1 million, marking a year-over-year increase of 74.50%. This contributed to the annual value of -$323.8 million for FY2024, which is 16.57% up from last year.
  • Per Travere Therapeutics' latest filing, its EBIT stood at $24.9 million for Q3 2025, which was up 297.08% from -$12.7 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' EBIT peaked at $24.9 million during Q3 2025, and registered a low of -$139.2 million during Q1 2024.
  • Its 3-year average for EBIT is -$67.5 million, with a median of -$67.7 million in 2024.
  • Per our database at Business Quant, Travere Therapeutics' EBIT crashed by 215.58% in 2021 and then spiked by 144.40% in 2025.
  • Travere Therapeutics' EBIT (Quarterly) stood at -$84.8 million in 2021, then dropped by 2.18% to -$86.7 million in 2022, then fell by 8.69% to -$94.2 million in 2023, then soared by 35.55% to -$60.7 million in 2024, then soared by 144.40% to $24.9 million in 2025.
  • Its EBIT stands at $24.9 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$42.7 million for Q1 2025.